Yervoy/Nivolumab Combo Keying Bristol’s Immuno-Oncology R&D Strategy

At the Morgan Stanley Healthcare Conference, recently promoted CSO Francis Cuss spoke about Bristol’s plans to test a combination of Yervoy and nivolumab in a variety of tumor types. The pharma’s near-term goals also center on label expansion for Eliquis and filing the first all-oral combination regimen for hepatitis C in Japan.